Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.

[1]  Volker Brauer,et al.  MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults , 2009, PloS one.

[2]  T. Chotpitayasunondh,et al.  Safety, Humoral and Cell Mediated Immune Responses to Two Formulations of an Inactivated, Split-Virion Influenza A/H5N1 Vaccine in Children , 2008, PloS one.

[3]  Z. Vajo,et al.  Safety and Immunogenicity of a Prepandemic Influenza A (H5N1) Vaccine in Children , 2008, The Pediatric infectious disease journal.

[4]  J. McVernon,et al.  Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. , 2008, Vaccine.

[5]  Thomas D Szucs,et al.  Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. , 2008, The Lancet. Infectious diseases.

[6]  G. Leroux-Roels,et al.  An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. , 2008, The Journal of infectious diseases.

[7]  Junbao Yang,et al.  Healthy Human Subjects Have CD4+ T Cells Directed against H5N1 Influenza Virus1 , 2008, The Journal of Immunology.

[8]  C. Agrati,et al.  Cross-subtype Immunity against Avian Influenza in Persons Recently Vaccinated for Influenza , 2008, Emerging infectious diseases.

[9]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[10]  K. Subbarao,et al.  Scientific barriers to developing vaccines against avian influenza viruses , 2007, Nature Reviews Immunology.

[11]  Yu Wang,et al.  Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial , 2006, The Lancet.

[12]  M. Zambon,et al.  Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.

[13]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[14]  Gregory A Poland,et al.  Vaccines against avian influenza--a race against time. , 2006, The New England journal of medicine.

[15]  P. Doherty,et al.  Cell-mediated Protection in Influenza Infection , 2006, Emerging infectious diseases.

[16]  J. Wood,et al.  Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. , 2005, Vaccine.

[17]  Prasert Auewarakul,et al.  Probable person-to-person transmission of avian influenza A (H5N1). , 2005, The New England journal of medicine.

[18]  Y. Guan,et al.  Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia , 2004, Nature.

[19]  A. Charlett,et al.  Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. , 2004, Virus research.

[20]  N. Verlander,et al.  Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial , 2003, The Lancet.

[21]  R. Webster,et al.  Eight-plasmid system for rapid generation of influenza virus vaccines. , 2002, Vaccine.

[22]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[23]  S. Epstein.  Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. , 2006, The Journal of infectious diseases.